208 related articles for article (PubMed ID: 23060579)
1. Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma--a SEER based study.
Chakraborty S; Hauke RJ; Bonthu N; Tarantolo SR
Anticancer Res; 2012 Oct; 32(10):4507-15. PubMed ID: 23060579
[TBL] [Abstract][Full Text] [Related]
2. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
3. Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study.
Ai WZ; Keegan TH; Press DJ; Yang J; Pincus LB; Kim YH; Chang ET
JAMA Dermatol; 2014 Jul; 150(7):709-15. PubMed ID: 24718769
[TBL] [Abstract][Full Text] [Related]
4. Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy.
Abdel-Wahab M; Reis IM; Hamilton K
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):58-68. PubMed ID: 18374503
[TBL] [Abstract][Full Text] [Related]
5. Trends in Risks for Second Primary Cancers Associated With Index Human Papillomavirus-Associated Cancers.
Suk R; Mahale P; Sonawane K; Sikora AG; Chhatwal J; Schmeler KM; Sigel K; Cantor SB; Chiao EY; Deshmukh AA
JAMA Netw Open; 2018 Sep; 1(5):e181999. PubMed ID: 30646145
[TBL] [Abstract][Full Text] [Related]
6. Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry.
Rihani R; Bazzeh F; Faqih N; Sultan I
Cancer; 2010 Sep; 116(18):4385-94. PubMed ID: 20549819
[TBL] [Abstract][Full Text] [Related]
7. Second Primary Malignancies in CTCL Patients from 1992 to 2011: A SEER-Based, Population-Based Study Evaluating Time from CTCL Diagnosis, Age, Sex, Stage, and CD30+ Subtype.
Amber KT; Bloom R; Nouri K
Am J Clin Dermatol; 2016 Feb; 17(1):71-7. PubMed ID: 26386881
[TBL] [Abstract][Full Text] [Related]
8. Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data.
Abdel-Wahab M; Reis IM; Wu J; Duncan R
Urology; 2009 Oct; 74(4):866-71. PubMed ID: 19628258
[TBL] [Abstract][Full Text] [Related]
9. Risk of Second Primary Tumors After Childhood and Adolescent Ovarian Malignancies: A SEER Analysis (1973-2011).
Nasioudis D; Ramer I; Sisti G; Fambrini M
J Pediatr Adolesc Gynecol; 2015 Dec; 28(6):522-5. PubMed ID: 26152647
[TBL] [Abstract][Full Text] [Related]
10. Association of First Primary Cancer With Risk of Subsequent Primary Cancer Among Survivors of Adult-Onset Cancers in the United States.
Sung H; Hyun N; Leach CR; Yabroff KR; Jemal A
JAMA; 2020 Dec; 324(24):2521-2535. PubMed ID: 33351041
[TBL] [Abstract][Full Text] [Related]
11. Second Primary Malignancies in Mantle Cell Lymphoma: A US Population-based Study.
Shah BK; Khanal A
Anticancer Res; 2015 Jun; 35(6):3437-40. PubMed ID: 26026107
[TBL] [Abstract][Full Text] [Related]
12. Leukemias, myeloma, and other lymphoreticular neoplasms.
Hernández JA; Land KJ; McKenna RW
Cancer; 1995 Jan; 75(1 Suppl):381-94. PubMed ID: 8001009
[TBL] [Abstract][Full Text] [Related]
13. Risk of a second malignant neoplasm among 5-year survivors of cancer in childhood and adolescence in British Columbia, Canada.
MacArthur AC; Spinelli JJ; Rogers PC; Goddard KJ; Phillips N; McBride ML
Pediatr Blood Cancer; 2007 Apr; 48(4):453-9. PubMed ID: 16767718
[TBL] [Abstract][Full Text] [Related]
14. Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).
Milano AF
J Insur Med; 2018; 47(4):203-211. PubMed ID: 30668210
[TBL] [Abstract][Full Text] [Related]
15. Incidence of second malignancies among patients treated with proton versus photon radiation.
Chung CS; Yock TI; Nelson K; Xu Y; Keating NL; Tarbell NJ
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):46-52. PubMed ID: 23778197
[TBL] [Abstract][Full Text] [Related]
16. Risk patterns of multiple myeloma in Los Angeles County, 1972-1999 (United States).
Gebregziabher M; Bernstein L; Wang Y; Cozen W
Cancer Causes Control; 2006 Sep; 17(7):931-8. PubMed ID: 16841260
[TBL] [Abstract][Full Text] [Related]
17. Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma.
Lee JS; DuBois SG; Boscardin WJ; Wustrack RL; Goldsby RE
Cancer; 2014 Dec; 120(24):3987-93. PubMed ID: 25116228
[TBL] [Abstract][Full Text] [Related]
18. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study.
Park SM; Lim MK; Jung KW; Shin SA; Yoo KY; Yun YH; Huh BY
J Clin Oncol; 2007 Oct; 25(30):4835-43. PubMed ID: 17947733
[TBL] [Abstract][Full Text] [Related]
19. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.
Hinnen KA; Schaapveld M; van Vulpen M; Battermann JJ; van der Poel H; van Oort IM; van Roermund JG; Monninkhof EM
J Clin Oncol; 2011 Dec; 29(34):4510-5. PubMed ID: 22025166
[TBL] [Abstract][Full Text] [Related]
20. Second malignancies in patients with Ewing Sarcoma Family of Tumors: A population-based study.
Sultan I; Rihani R; Hazin R; Rodriguez-Galindo C
Acta Oncol; 2010; 49(2):237-44. PubMed ID: 20100158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
